Oncology R&D investment has been consistently increasing. A case in point: Of the 65000 trials registered on, there are approx. 19000 product related ongoing trials. It´s noteworthy that a trial´s probability of success hasn´t increased over the years i.e. most of these trials face a higher risk of failure than ever before. A few highlights from 2018: 15 new drugs launched for 17 indications Currently >700 companies are undertaking clinical development activities; of these
Rx Usage
The latest report from the IQVIA™ Institute for Human Data Science presents the 2018 Medicines Use and Spending in the U.S. The report provides extensive metrics on drug usage and its cost to the US Healthcare system. We discuss some of the interesting findings of this report. 2018 witnessed a 2.7% growth in the total prescriptions dispensed and an increase of 4.5% in net spending (defined as the amount received by pharmaceutical manufacturers after rebates,
Beyond the hype surrounding #ArtificalIntelligence, #MachineLearning and #DeepLearning, there are several serious research groups working on developing AI based technologies to improve healthcare. At ASCO19, several academic and industry groups presented the outcomes of their research in developing tools for improving oncology healthcare. The range of presentations was wide – Identifying new biological targets, algorithm driven diagnosis (including staging) and prognosis, treatment response analysis and predicting patient outcomes. Beyond the classical AI discovery-to-outcomes applications, few